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1  | INTRODUC TION
Candida is a major cause of nosocomial infections,1 and candidae-
mia causes significant mortality ranging between 30% and 45%.2-5 
Furthermore, candidaemia generates significant healthcare 
costs.2 Its main complications include metastatic infection foci 
and death.6
Persistent candidaemia (PC) is frequently recognised as an-
other complication of candidaemia. Underlying factors that can in-
fluence the persistence of blood culture positivity in candidaemia 
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Summary
Objectives: Persistent candidaemia (PC) is a recognised complication of candidae-
mia. Our objective was to evaluate risk factors and clinical significance of PC in adult 
patients.
Methods: This is a retrospective, cohort study. We compared PC with non-PC. All 
patients with blood cultures positive for Candida species were identified from a mi-
crobiological database in the hospital district of Helsinki and Uusimaa from 2007 to 
2016. PC was defined as an isolation of the same Candida species from positive blood 
culture for ≥5 days.
Results: PC criteria were fulfilled by 75/350 patients (21.4%). No significant differ-
ence emerged between persistent and non-persistent cases caused by non-albicans 
Candida species (37.3% vs 35.1%, P = .742). The length of hospital stay before onset of 
candidaemia was longer before PC (hospital stay > 7 days; 73.3% vs 59.6%, P = .043). 
No significant impact on 30-day mortality was observed (20.0% vs 15.5%, P = .422). 
Using multivariable regression analysis, we found the presence of central venous 
catheter (CVC) (OR = 2.71, 95% CI 1.31-5.59), metastatic infection foci (OR 3.60, 95% 
CI 1.66-7.79) and ineffective empirical treatment (OR = 3.31, 95% CI 1.43-7.65) to be 
independent risk factors for PC. In subgroup analysis, early source control was identi-
fied as a protective factor against PC (30.5% vs 57.7%, P = .002).
Conclusion: The presence of CVC, metastatic infection foci and ineffective empirical 
treatment were independently associated with PC in adult patients. Active search for 
and treatment of metastatic infection foci and removal of CVC are key elements for 
preventing PC.
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include the host's baseline characteristics (eg cancer, immunosup-
pressive medication, neutropenia), antifungal resistance, efficacy 
of therapeutic management and source control. However, the lit-
erature on PC is scarce. The most relevant problem in evaluating 
PC is the lack of a homogeneous definition of PC.7 Most studies 
evaluating PC include adult and child populations or have been 
conducted only in neonatal populations.2,8-11 This complicates any 
generalisation of the results to adult patients. The definition of 
PC ranges from >1 day to 7 days in literature, which influences 
PC incidence rates.7 The reported incidence rates of PC vary from 
8% to 93%.7 However, the reported rates are at 11%-37% when 
considering only studies with a definition of candidaemia duration 
of 3-5 days.12-15 Although several studies have evaluated PC, the 
data are mostly from research designed to consider other ele-
ments than PC.16-18
The aim of this study was to evaluate the underlying risk factors 
and clinical significance of PC, defined as blood culture positivity 
persisting for 5 days or longer. We compared adult patients with PC 
with non-persistent cases in a retrospective analysis from Southern 
Finland during 2007-2016.
2  | PATIENTS AND METHODS
2.1 | Study design
An observational, retrospective cohort study including adult pa-
tients with candidaemia was conducted in the hospital district 
of Helsinki and Uusimaa (population 1.6 million) in Finland from 
January 2007 to December 2016. All patients with blood cultures 
positive for Candida species were identified from the laboratory 
database. Patients aged under 18 years were excluded. The clini-
cal data were collected from the cases treated in secondary and 
tertiary care hospitals. Patient demographics and medical history, 
including age, sex, admitted ward, underlying diseases, a primary 
source of infection, risk factors for candidaemia, catheter removal, 
Candida species, laboratory findings, details of antimicrobial sus-
ceptibility results and antimicrobial therapy, were reviewed. The 
persistent and non-persistent candidaemia cases were identified 
and compared to evaluate the underlying causes and clinical sig-
nificance of PC. Complications and 30-day overall mortality were 
assessed.
Details of microbiological identification and susceptibility testing 
are presented in an earlier publication of this study.19 As earlier has 
been described, identification of Candida isolates was based on tra-
ditional methods using morphological and biochemical features (ID 
32 C®, bioMérieux) before 2012. Since 2012, the strains have been 
mainly identified by MALDI-TOF technology (Vitek MS, bioMérieux) 
and by sequencing of the ITS gene,20 if necessary. Susceptibility test-
ing was performed using agar diffusion method (Etest®, bioMérieux) 
according to the manufacturer's instructions. The results were in-
terpreted by using the CLSI breakpoints until the end of 2010. 
Interpretation has been conducted according to the EUCAST clinical 
breakpoint since the beginning of 2011. The susceptibility testing for 
anidulafungin started routinely in 2011, and earlier it was performed 
on demand.
The authors confirm adherence to the ethical policies of the jour-
nal. The study protocol was approved by the review board of the 
Inflammation Center at Helsinki University Hospital. No informed 
consent was needed because of the retrospective nature of the 
study.
2.2 | Definitions
An episode of candidaemia was defined as at least one blood cul-
ture positive for Candida species. If the patient had more than one 
episode of candidaemia, only the first episode was included in the 
study. Recurrent episodes were excluded (n = 24). PC was defined 
as an isolation of the same Candida species from any positive blood 
culture taken ≥5 days after the first positive blood samples were 
drawn. Non-PC was defined as all other candidaemia cases than 
persistent ones with negative blood cultures taken at least once. 
Patients were excluded if death occurred <5 days after the onset of 
candidaemia (n = 7), if no antifungal treatment was provided(n = 6), 
or if no negative blood cultures were drawn (n = 90). Patient records 
were evaluated from tertiary and secondary care hospitals. Twenty-
one cases were treated in primary care hospitals, and the medical 
records were incomplete. These patients were excluded. Metastatic 
complications were considered endophthalmitis or chorioretinitis, 
endocarditis or pericarditis, vascular complications, and dissemina-
tion to other solid organs. Source control and its timing were as-
sessed, including abscess drainage, catheter removal, resolution of 
urinary tract obstruction or treatment for gastrointestinal perfora-
tion. Source control was regarded as early when performed within 
48 hours after onset of candidaemia. Empirical antifungal treatment 
was defined as treatment started on clinical suspicion of candidae-
mia before confirmation of candidaemia diagnosis. Antifungal treat-
ment was considered ineffective if the Candida species isolated 
from blood cultures was resistant to the initially administered an-
tifungal agent.
Neutropenia was specified as a neutrophil count of less than 
0.5 x 109/L occurring within the last two weeks before the onset 
of candidaemia. Comorbidities were evaluated using the McCabe 
classification.21 It classifies the severity of underlying illnesses with 
a score 1-3, where 1 indicates non-fatal prognosis (≥5 years), 2 in-
dicates an ultimately fatal prognosis (in 1-4 years) and 3 represents 
a rapidly fatal prognosis (within 1 year). Prior corticosteroid treat-
ment was defined as a use of prednisolone dose ≥ 15 mg/d for more 
than 3 weeks. Adherence to the guidelines of the European Society 
for Clinical Microbiology and Infectious Diseases (ESCMID) and 
the Infectious Diseases Society of America (IDSA) was evaluated 
using the EQUAL Candida Score of the European Confederation of 
Medical Mycology (ECMM).22 The maximum score was 22 points for 
patients with a central venous catheter (CVC) and 19 for those with-
out a CVC.
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2.3 | Statistical analysis
Categorical variables were summarised as counts and percentages 
and compared using the chi-square or Fisher's exact test, as appro-
priate. Continuous variables with a non-normal distribution were 
described as median and interquartile range (IQR) and compared 
using the Mann-Whitney U test. P-values ≤ .05 were considered to 
indicate statistical significance. Odds ratios (ORs) were calculated 
with 95% confidence interval (CI). Risk factors associated with PC 
were computed in a multivariable logistic regression analysis. The 
regression analysis included variables having univariate P-value < .1 
and was not multicollinear. SPSS version 25 (SPSS Inc) was used for 
all analyses.
3  | RESULTS
We identified a total of 374 episodes of candidaemia in 350 adult pa-
tients in our hospital district during the study period. The definition 
of PC was fulfilled by 75/350 cases (21.4%), while 151/350 cases 
(43.1%) were considered non-persistent.
The median duration of blood culture positivity in PC was 
9.0 days (IQR 7.0-15.0). The median number of follow-up blood cul-
tures was 5.0 (IQR 3.0-8.0, range 2-44) per patient. In many of the 
cases, control blood cultures were taken every other or every third 
day, but the follow-up blood cultures were taken daily for only 9.7% 
of the patients (22/226). Species distributions and susceptibility re-
sults are shown in Table 1. Non-albicans Candida spp. caused 37.3% 
of PC and 35.1% of non-persistent cases without a significant dif-
ference (P = .742). However, candidaemia caused by C dubliniensis 
was more common among non-persistent than PC cases (PC 1.3% 
vs non-PC 7.9%), but the difference did not reach statistical signif-
icance (P = .065). C albicans was the leading cause (62.7%) of PC, 
followed by C glabrata (17.3%) and C parapsilosis (5.3%). Resistance 
rate for fluconazole was overall 21.3% for PC and 13.9% for non-per-
sistent cases (Table 1). Fluconazole resistance was rare (2.2%) for 
Candida spp. other than C glabrata, but the rate was high among 
PC (76.9%) and non-persistent cases (80.0%) caused by C glabrata. 
Anidulafungin susceptibility testing has been performed routinely 
since 2011 in our hospital district and earlier for only selected cases. 
Resistance to anidulafungin was rare, seen in only 4/168 cases 
(2.4%). Amphotericin B resistance was also rare; a total of 2/225 
cases (0.9%) were resistant to amphotericin B.
The baseline characteristics of PC vs non-persistent cases 
are displayed in Table 2. The median age for persistent cases was 
61.0 years (IQR 50.0-70.0) and for non-persistent cases 62.0 years 
(IQR 48.0-73.0). Among persistent cases, 57.3% were male, as 
were 64.2% of non-persistent cases. No significant difference be-
tween the two groups emerged regarding age, gender, comorbidi-
ties or prior drug exposures. However, previous use of fluconazole 
 
Persistent n (%), 
n = 75
Non-persistent n (%), 
n = 151 P
Albicans vs non-albicans Candida 
spp.
  .742
C albicans 47/75 (62.7) 98/151 (64.9)  
Non-albicans 28/75 (37.3) 53/151 (35.1)  
Candida species   .232
C albicans 47 (62.7) 98 (64.9)  
C glabrata 13 (17.3) 20 (13.2) .418
C parapsilosis 4 (5.3) 5 (3.3)  
C tropicalis 3 (4.0) 3 (2.0)  
C krusei 3 (4.0) 1 (0.7)  
C dubliniensis 1 (1.3) 12 (7.9) .065
Others or multiple 4 (5.3) 12 (7.9)  
Fluconazole resistance rate
All 16/75 (21.3) 21/151 (13.9)  
C albicans 1/47 (2.1) 1/98 (1.0)  
C glabrata 10/13 (76.9) 16/20 (80.0)  
C parapsilosis 1/ 4 (25.0) 1/ 5 (20.0)  
C tropicalis 0/3 0/3  
Anidulafungin resistance rate 2/56 (3.6) 2/112 (1.8)  
C albicans 0/33 0/70  
C glabrata 0/10 1/17 (5.9)  
Abbreviation: Spp, species
TA B L E  1   Candida bloodstream 
isolates in persistent vs non-persistent 
candidaemia
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was slightly more frequent before diagnosis for PC than before 
non-PC diagnosis (24.0% vs 15.9%, respectively, P = .140). 
Persistent cases were diagnosed less at medical departments 
(16.0% vs 27.2%, P = .062), with half of the cases diagnosed at 
surgical departments. The association of prior gastrointestinal 
(GI) surgery with PC was significant (32.0% vs 18.5%, P = .024) in 




n (%) n (%)
n = 75 n = 151
Male 43 (57.3) 97 (64.2) .314
Age (median, IQR) 61.0 (50.0-70.0) 62.0 (48.0-73.0) .424
Department at onset of candidaemia
ICU 12 (16.0) 16 (10.6) 1
Surgical 37 (49.3) 64 (42.4) .549
Medical 12 (16.0) 41 (27.2) .062
Haematology-oncology 5 (6.7) 8 (5.3) .790
Others 9 (12.0) 22 (14.6) .270
ICU
ICU at onset of candidaemia 12 (16.0) 16 (10.6) .246
Admission to ICU after onset of candidaemia 7 (9.3) 14 (9.3) .988
ICU before candidaemia diagnosis within 30 d 24 (32.0) 35 (23.2) .155
Comorbidities
McCabe
1 20 (26.7) 53 (35.1) 1
2 40 (53.3) 68 (45.0) .178
3 15 (20.0) 30 (19.9) .493
Diabetes mellitus
Malignancy 18 (24.0) 34 (22.5) .867
Solid organ tumour 17 (22.7) 28 (18.5) .465
Haematological malignancy 6 (8.0) 15 (9.9) .639
Predisposing factors
Dialysis 10 (13.3) 11 (7.3) .140
Intravenous drug abuse 6 (8.0) 21 (13.9) .276
Prior GI surgery 24 (32.0) 28 (18.5) .024
Neutropenia 5 (6.7) 11 (7.3) .865
Chemotherapy 6 (8.0) 11 (7.3) .848
Solid organ transplantation 2 (2.7) 3 (2.0) 1.000
Hematopoietic stem cell transplantation 2 (2.7) 7 (4.6) .721
Concomitant bacteremia within ±3 d 10 (13.3) 23 (15.2) .704
Prior drug exposure
Antibioticsa  39 (35.1) 72 (47.7) .541
Fluconazoleb  18/74 (24.3) 24 (15.9) .140
Corticosteroids 6 (8.0) 11 (7.3) .848
Other immunosuppressive medication 4 (5.3) 10 (6.6) .705
Length of hospital stay prior to candidaemia
0-7 d 20 (26.7) 61 (40.4)  
>7 d 55 ( 73.3) 90 (59.6) .043
Abbreviations: GI, gastrointestinal; ICU, intensive care unit; IQR, interquartile range.
aBroad-spectrum antibiotics with anaerobic coverage. 
bData are missing for one PC case. 
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univariate analysis. Length of hospital stay before onset of PC as 
opposed to non-PC was longer (hospital stay > 7 days; PC 73.3% 
vs non-PC 59.6%, P = .043).
Therapeutic management and clinical outcome are shown in 
Table 3. Fluconazole was the most common initial antifungal agent 
for both PC and non-PC (54.1% vs 62.9%, P = .202). Overall, an effec-
tive antifungal therapy was started empirically for 15.9% (36/226) 
of all patients without a significant difference between the groups 
(17.3% vs 15.2%, P = .329). However, an ineffective antifungal agent 
was started empirically more often for persistent than non-per-
sistent cases (22.7% vs 10.6%, P = .011). The median duration of an 
ineffective treatment after the first positive blood culture was drawn 
was 2.5 days (IQR 1.75-4.5, range 1-6 days) for PC and 1.9 days (IQR 
1.0-2.0, range 1-7 days) for non-PC.
The presence of CVC (68.0% vs 46.4%, P = .002) and catheter-re-
lated infection (42.7% vs 19.2%, P = .003) were more common in PC 
than in non-PC. A significant association was observed with met-
astatic infection foci between persistent and non-persistent cases 
(29.3% vs 13.2%, P = .003). Patients with PC had more ocular candi-
diasis (9.3% vs 2.6%, P = .045), other solid organ complications (18.7% 
vs 8.6%, P = .028) and vascular complications (6.7% vs 0.7%,P = .016) 
than non-persistent cases. Vascular complications (n = 6) included 
infected thromboses or thrombophlebitis (4/6, 66.7%) and infection 
of intravascular prostheses (2/6, 33.3%). Other solid organ compli-
cations (n = 27) comprised abscesses (6/27, 22.2%), pulmonary le-
sions (10/27, 37.0%), infection of prosthetic devices (3/27, 11.1%), 
osteomyelitis (2/27, 7.4%) and dissemination to several organs (6/27, 
22.2%). During the 10-year study period, the overall 30-day mortal-
ity of candidaemia in the hospital district of Helsinki and Uusimaa 
was 31%. The 30-day mortality rate was 20.0% for PC and 13.9% for 
non-PC (P = .239).
The EQUAL Candida Score was calculated to analyse adherence 
to guidelines. The median EQUAL Candida Score was 13.0 (IQR 11.0-
15.0, range 8-21). The median score for patients with CVC was 14.0 
(IQR 11.0-16.0, range 8-21) and for patients without CVC 11.0 (IQR 
11.0-14.0, range 8-18). Echocardiography was performed for 53.1% 
(120/226) and ophthalmoscopy for only 23.5% (53/226) of patients. 
Follow-up blood cultures were taken daily only for 9.7% (22/226) 
of the patients. Adherence was higher in patients who survived 
30 days after onset of candidaemia than in non-survivors (P = .004). 
TA B L E  3   Therapeutic management and outcome of persistent vs non-persistent candidaemia
 Persistent n (%), n = 75 Non-persistent n (%), n = 151 P
Initial antifungal therapy
Fluconazole 40 (54.1) 95 (62.9) .202
Echinocandin 33 (44.6) 53 (35.1) .169
Other or combination 1 (1.4) 3 (2.0)  
Empirical antifungal therapy
AF started after blood culture result available 36 (48.0) 94 (62.3) 1
Effective AF started empirically 13 (17.3) 23 (15.2) .329
AF empirically with suboptimal dose 9 (12.0) 18 (11.9) .556
Ineffective empirical AF 17 (22.7) 16 (10.6) .011
Source of infection
Primary 5 (6.7) 23 (15.2) 1
Catheter-related 32 (42.7) 29 (19.2) .003
GI 22 (29.3) 43 (28.5) .126
Urinary 5 (6.7) 27 (17.9) .817
Other 11 (14.7) 29 (19.2) .359
Source control
Source control during infection within applicable cases 52/59 (88.1) 75/78 (96.2) .100
Early source control (<48 h) within applicable cases 18/59 (30.5) 45 /78 (57.7) .002
Central venous catheter 51 (68.0) 70 (46.4) .002
Early removal of CVC (<48 h) in applicable cases 24/51 (47.1) 32/70 (45.7) .884
Patients with metastatic infection foci 22 (29.3) 20 (13.2) .003
Endophthalmitis or retinitis 7 (9.3) 4 (2.6) .045
Endocarditis or pericarditis 3 (4.0) 3 (2.0) .401
Vascular complication 5 (6.7) 1 (0.7) .016
Other solid organ complication 14 (18.7) 13 (8.6) .028
30-d mortality 15 (20.0) 21 (13.9) .239
Abbreviations: AF, antifungal; CVC, central venous catheter; GI, gastrointestinal.
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However, no significant difference in guideline adherence was pres-
ent between PC and non-PC cases (median score for PC 13.0 vs for 
non-PC 12.0, P = .068).
Using multivariable regression analysis (Table 4), we found the 
presence of CVC (OR = 2.71; 95% CI 1.31-5.59), metastatic infection 
foci (OR = 3.60; 95% CI 1.66-7.79) and ineffective empirical treat-
ment (OR = 3.31; 95% CI 1.43-7.65) to be independent risk factors 
for PC. An applicable source of infection for source control was iden-
tified for 59 PC cases and for 78 non-PC cases (Table 3). In subgroup 
analysis, an early source control (within <48 hours of candidaemia 
onset) was more common in non-PC (PC 30.5% vs non-PC 57.7%, 
P = .002).
4  | DISCUSSION
We investigated the risk factors and clinical significance of PC in 
adult patients during a 10-year study period. Persistent candidae-
mia was found in 75 cases during the study period. Factors indepen-
dently associated with PC were the presence of CVC at the onset of 
candidaemia, metastatic infection foci and ineffective empirical an-
tifungal treatment. Catheter-related infection was the most common 
source of infection in persistent cases. CVC has been demonstrated 
as a risk factor for PC in other studies as well.11,23-25 However, a re-
cent cohort study conducted in adult patients did not find a signifi-
cant association between CVC andPC.12 In their study, CVC was a 
very common finding overall in both PC and non-PC groups (80% vs 
72%), but the difference did not reach statistical significance.
The presence of CVC is a prominent risk factor for PC; however, 
the timing of CVC removal is complex. The association between 
early removal of CVC and PC was not significant in our study, sup-
ported by another recent study.24 Nucci et al26 showed that early 
CVC removal had no effect on persistent or recurrent candidaemia 
or time to mycological eradication, although earlier studies have re-
ported an association of improved outcome and faster mycological 
eradication with prompt CVC removal.27,28
Metastatic infection foci were more prominent in PC than in 
non-PC cases. Similarly, unexpected additional infection sites were 
associated with PC also in an earlier analysis.12 This supports the as-
sumption that an active search for metastatic infection foci is crucial 
during the treatment of PC. Early source control was a protective 
factor against PC in a subgroup analysis in our study.
Fluconazole resistance among C glabrata isolates was high in 
both PC and non-PC, but no significant difference emerged be-
tween the groups. Otherwise, resistance to antifungals was rare. 
Ineffective empirical antifungal treatment was associated with PC in 
our study. Ineffective antifungal was started before the results from 
blood cultures were available, but all of these patients who received 
ineffective antifungal initially received appropriate antifungal after 
the culture results were disclosed. Relatively many patients (22% of 
PC and 11% of non-PC cases) initially received an ineffective agent, 
even though the median duration of the ineffective therapy was 
short. Half of the inappropriate treatment was prescribed at surgical 
departments. Treatment with fluconazole or echinocandin as an ini-
tial antifungal showed no significant difference between persistent 
and non-persistent cases.
Neonatal analyses have demonstrated an association between 
PC and non-albicans Candida species.9,11 Our results reflected no 
such association in an adult population, consistent with the findings 
of other studies conducted in adult populations.12,23 This indicates 
an overall difference in species distribution between adult and child 
populations. C parapsilosis is a more common cause of candidaemia 
in children than in adults,29,30 and this might not be a finding specific 
to PC C. albicans was the leading cause of both PC and non-PC in 
our study; it is the leading cause of candidaemia overall in Northern 
Europe.29,31-33
Underlying factors, such as malignancies, neutropenia, severe 
comorbidities and transplantation, have been identified as risk 
factors for candidaemia.34 However, these factors were not as-
sociated significantly more frequently with PC than non-PC in our 
study. The overall 30-day mortality rate in our hospital district was 
31% during the study period, which is slightly lower than earlier 
finding in Finland. The one-month case fatality rate was 35% in 
a population-based study conducted in Finland in 2004-2007.35 
The use of echinocandins has increased as an initial therapy for 
candidaemia during the same period, and it might have decreased 
the mortality rate. The overall 30-day mortality rate was sim-
ilar to figures reported in other Nordic countries: Iceland (30%, 
2013), Norway (36%, 2019) and Denmark (37%, 2011 and 43%, 
2018).5,29,31,36 The 30-day mortality was 20.0% in PC and 13.9% 
TA B L E  4   Multivariable regression analysis for independent risk factors of persistent candidaemia
 Univariate OR 95% CI P Multivariable OR 95% CI P
Medical department during candidaemia 
diagnosis
0.51 0.25-1.04 .065 0.54 0.24-1.17 .118
CVC 2.46 1.38-4.40 .002 2.71 1.31-5.59 .007
Prior GI surgery 2.07 1.10-3.90 .025 1.28 0.61-2.68 .521
Metastatic infection foci 2.72 1.37-5.39 .004 3.60 1.66-7.79 .001
C dubliniensis 0.16 0.02-1.23 .078 0.21 0.03-1.70 .143
Ineffective empirical treatment 2.47 1.17-5.23 .018 3.31 1.43-7.65 .005
Hospital stay > 7 d before candidaemia diagnosis 1.86 1.02-3.42 .044 1.37 0.67-2.80 .392
Abbreviations: CI, confidence interval; CVC, central venous catheter; GI, gastrointestinal; OR, odds ratio.
     |  7ALA-HOUHALA And AnTTILA
in non-PC in our study, but the difference did not reach statistical 
significance. Surprisingly, the overall 30-day mortality rate was 
lower in PC than overall in our hospital district or in general in 
candidaemia.2-5 Candidaemia is associated with severe underlying 
comorbidities, for example malignancies.36 Sometimes, it is justi-
fied to focus on symptomatic treatment and refrain from control 
blood cultures if the patient is in a terminal phase. Patients who 
died within five days or had no negative blood cultures taken were 
excluded from our analysis. When we excluded these patients, it 
decreased the mortality rate in PC and non-PC groups.
Adherence to guidelines was evaluated with the Equal Candida 
Score. The score showed an association with mortality, but not with 
PC. A recent study from Taiwan reported a significant association 
with survival outcome as well.37 However, other previous studies 
have not found a significant difference,38-40 despite survivors having 
higher Equal Candida Scores than non-survivors. The patient number 
was smaller in these studies. The median score was 13.0 in our study. 
There is still a long way to go to achieve an excellent rating according to 
ESCMID and IDSA guidelines.
Our study has several potential limitations. The most significant 
one is the retrospective nature of the analysis. Follow-up blood cul-
tures are strongly recommended, but there were no predesigned 
routines for follow-up blood cultures during the study period. 
Monitoring infection clearance from blood cultures is often ne-
glected if a patient responds very well to treatment or if the patient 
is terminally ill. However, this study provides reliable data over a 10-
year study period for adult patients.
In conclusion, the presence of CVC, metastatic infection foci and 
ineffective empirical antifungal were independent risk factors for 
PC. Active search for and treatment of metastatic infection foci, and 
removal of CVC are the key elements for improving patient care and 
preventing PC.
CONFLIC T OF INTERE S T
MAH has received lecture fee from MSD and Gilead and confer-
ence invitations from Pfizer and MSD. VJA has received lecture 
fees from Pfizer, MSD, Astellas, Unimedic, Roche, BMS, Biogen 
and Gilead; has participated as PI to Varicella zoster vaccination 
studies; and has received a study grant for a pneumococcal vac-
cination study.
AUTHORS'  CONTRIBUTION
MAH and VJA conceived the study design. MAH has collected and 
analysed the data. Both authors drafted the manuscript and ap-
proved the final version of the manuscript.
ORCID
Mari Ala-Houhala  https://orcid.org/0000-0002-5140-0587 
R E FE R E N C E S
 1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidi-
asis: a persistent public health problem. Clin Microbiol Rev. 
2007;20(1):133-163.
 2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The ep-
idemiology and attributable outcomes of candidemia in adults and 
children hospitalized in the United States: a propensity analysis. Clin 
Infect Dis. 2005;41(9):1232-1239.
 3. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology 
and predictive factors for early and late mortality in candida blood-
stream infections: A population-based surveillance in spain. Clin 
Microbiol Infect. 2014;20(4):O245-O254.
 4. Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribu-
tion, antifungal susceptibility, and outcome of candidemia across 
five sites in italy and spain. J Clin Microbiol. 2013;51(12):4167-4172.
 5. Lausch KR, Søgaard M, Rosenvinge FS, et al. High incidence of can-
didaemia in a nationwide cohort: Underlying diseases, risk factors 
and mortality. Int J Infect Dis. 2018;76:58-63.
 6. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 
2006;20(3):485-506.
 7. Nucci M. Persistent candidemia: Causes and investigations. Curr 
Fungal Infect Rep. 2011;5:3-11.
 8. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk 
factors for disseminated candidiasis in children with candidemia. 
Pediatr Infect Dis J. 2004;23(7):635-641.
 9. Fu J, Ding Y, Jiang Y, Mo S, Xu S, Qin P. Persistent candidemia in 
very low birth weight neonates: Risk factors and clinical signifi-
cance. BMC Infect Dis. 2018;18(1):558–018-3487-9.
 10. Robinson JA, Pham HD, Bloom BT, Wittler RR. Risk factors for per-
sistent candidemia infection in a neonatal intensive care unit and 
its effect on mortality and length of hospitalization. J Perinatol. 
2012;32(8):621-625.
 11. Hammoud MS, Al-Taiar A, Fouad M, Raina A, Khan Z. Persistent 
candidemia in neonatal care units: Risk factors and clinical signifi-
cance. Int J Infect Dis. 2013;17(8):e624-e628.
 12. Agnelli C, Valerio M, Bouza E, et al. Persistent candidemia in adults: 
Underlying causes and clinical significance in the antifungal stew-
ardship era. Eur J Clin Microbiol Infect Dis. 2019;38(3):607-614.
 13. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a ter-
tiary care cancer center: In vitro susceptibility and its association 
with outcome of initial antifungal therapy. Medicine (Baltimore). 
2003;82(5):309-321.
 14. Safdar A, Bannister TW, Safdar Z. The predictors of outcome in 
immunocompetent patients with hematogenous candidiasis. Int J 
Infect Dis. 2004;8(3):180-186.
 15. Velasco E, Bigni R. A prospective cohort study evaluating the prog-
nostic impact of clinical characteristics and comorbid conditions of 
hospitalized adult and pediatric cancer patients with candidemia. 
Eur J Clin Microbiol Infect Dis. 2008;27(11):1071-1078.
 16. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin vs caspo-
fungin for treatment of candidemia and other forms of invasive 
candidiasis. Clin Infect Dis. 2007;45(7):883-893.
 17. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial 
candidaemia in non-neutropenic patients in an italian tertiary hos-
pital. Clin Microbiol Infect. 2005;11(11):908-913.
 18. Reboli AC, Shorr AF, Rotstein C, et al. Anidulafungin compared with 
fluconazole for treatment of candidemia and other forms of inva-
sive candidiasis caused by candida albicans: A multivariate analy-
sis of factors associated with improved outcome. BMC Infect Dis. 
2011;11:261–2334-11-261.
 19. Ala-Houhala M, Valkonen M, Kolho E, Friberg N, Anttila VJ. Clinical 
and microbiological factors associated with mortality in candidemia 
in adult patients 2007–2016. Infect Dis. 2019;51(11–12):824-830.
 20. Ala-Houhala M, Koukila-Kahkola P, Antikainen J, Valve J, Kirveskari 
J, Anttila VJ. Clinical use of fungal PCR from deep tissue samples in 
the diagnosis of invasive fungal diseases: a retrospective observa-
tional study. Clin Microbiol Infect. 2017;24(3):301-305.
 21. McCabe WR, Jackson GG. Gram-negative bacteremia. I.etiology 
and ecology. Arch Intern Med. 1962;10(6):847-855.
8  |     ALA-HOUHALA And AnTTILA
 22. Mellinghoff SC, Hoenigl M, Koehler P, et al. EQUAL candida score: 
An ECMM score derived from current guidelines to measure QUAlity 
of clinical candidaemia management. Mycoses. 2018;61(5):326-330.
 23. Kang SJ, Kim SE, Kim UJ, et al. Clinical characteristics and risk fac-
tors for mortality in adult patients with persistent candidemia. J 
Infect. 2017;75(3):246-253.
 24. Li WS, Chen YC, Kuo SF, Chen FJ, Lee CH. The impact of bio-
film formation on the persistence of candidemia. Front Microbiol. 
2018;9:1196.
 25. Ortega M, Marco F, Soriano A, et al. Candida species bloodstream 
infection: Epidemiology and outcome in a single institution from 
1991 to 2008. J Hosp Infect. 2011;77(2):157-161.
 26. Nucci M, Anaissie E, Betts R, et al. Early removal of central venous 
catheter in patients with candidemia does not improve outcome: 
analysis of 842 patients from 2 randomized clinical trials. Clin Infect 
Dis. 2010;51(3):295-303.
 27. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia 
in non-neutropenic patients at an italian tertiary care hospital. Eur J 
Clin Microbiol Infect Dis. 2000;19(8):602-607.
 28. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange 
and duration of candidemia. NIAID mycoses study group and the 
candidemia study group. Clin Infect Dis. 1995;21(4):994-996.
 29. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide 
study of candidemia, antifungal use, and antifungal drug resistance 
in iceland, 2000 to 2011. J Clin Microbiol. 2013;51(3):841-848.
 30. Hesstvedt L, Gaustad P, Andersen CT, et al. Twenty-two years of 
candidaemia surveillance: results from a norwegian national study. 
Clin Microbiol Infect. 2015;21(10):938-945.
 31. Hesstvedt L, Gaustad P, Müller F, et al. The impact of age on risk 
assessment, therapeutic practice and outcome in candidemia. Infect 
Dis (Lond). 2019;51(6):425-434.
 32. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes 
with potential implication for antifungal prescription recommenda-
tions for fungaemia: Data from a nationwide fungaemia surveillance 
programme. Clin Microbiol Infect. 2013;19(8):E343-E353.
 33. Klingspor L, Ullberg M, Rydberg J, et al. Epidemiology of fungae-
mia in Sweden: a nationwide retrospective observational survey. 
Mycoses. 2018;61(10):777-785.
 34. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 
2015;373(15):1445-1456.
 35. Poikonen E, Lyytikäinen O, Anttila V-J, et al. Secular trend in candi-
demia and the use of fluconazole in finland, 2004–2007. BMC Infect 
Dis. 2010;10:312–2334-10-312.
 36. Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical 
characteristics, and outcomes for patients with fungemia. J Clin 
Microbiol. 2011;49(9):3300-3308.
 37. Huang HY, Lu PL, Wang YL, Chen TC, Chang K, Lin SY. Usefulness 
of EQUAL candida scores for predicting outcomes in patients with 
candidemia: A retrospective cohort study. Clin Microbiol Infect. 
2020. pii: S1198-743X(20)30055-0. https://doi.org/10.1016/j.
cmi.2020.01.029. [Epub ahead of print].
 38. Pinto-Magalhães S, Martins A, Lacerda S, et al. Candidemia in a por-
tuguese tertiary care hospital: analysis of a 2-year period. J Mycol 
Med. 2019;29(4):320-324.
 39. Mellinghoff SC, Hartmann P, Cornely FB, et al. Analyzing candi-
demia guideline adherence identifies opportunities for antifungal 
stewardship. Eur J Clin Microbiol Infect Dis. 2018;37(8):1563-1571.
 40. Nemer S, Imtiaz T, Varikkara M, Collier A, Bal AM. Management 
of candidaemia with reference to the european confedera-
tion of medical mycology quality indicators. Infect Dis (Lond). 
2019;51(7):527-533.
How to cite this article: Ala-Houhala M, Anttila V-J. 
Persistent vs non-persistent candidaemia in adult patients in 
2007-2016: A retrospective cohort study. Mycoses. 
2020;00:1–8. https://doi.org/10.1111/myc.13085
